Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults

Author:

Stoniute Akvile1,Madhuvrata Priya2,Still Madeleine1,Barron-Millar Evelyn1,Nabi Ghulam3,Omar Muhammad Imran45

Affiliation:

1. Evidence Synthesis Group, Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK

2. Obstetrics & Gynaecology; Sheffield Teaching Hospital NHS Foundation Trust; Sheffield UK

3. Section of Academic Urology, Division of Cancer Research; University of Dundee; Dundee UK

4. Guidelines Office; European Association of Urology; Arnhem Netherlands

5. Academic Urology Unit; University of Aberdeen; Aberdeen UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference676 articles.

1. Abrams P Jackson S Mattiasson A Krishnan K Haendler L A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract) International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece 1996 276 7

2. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder;Abrams;British Journal of Urology,1998

3. Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract);Abrams;Journal of Urology,1997

4. Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract);Abrams;Neurourology and Urodynamics,2001

5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY);Abrams;World Journal of Urology,2017

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3